Latest Advances in Lung Cancer Research

Imfinzi increases five year survival to 43% in patients with Stage III non-small cell lung cancer. After treatment, 43% survive 5+ years.

Dr. Karen Marrone discusses the role of postoperative radiotherapy (PORT) in early-stages of non-small cell lung cancer (NSCLC).

Diverse workforce in oncology: Improvement of inclusion and equity critical to reducing health disparities in cancer care.

No link to outside article.

Immunotherapy + Chemo Boosts Response for NSCLC patients with resectable tumors, new study out of Johns Hopkins University, Baltimore shows.

New NSCLC targeted therapy guidelines have been published. They are updates to the 2017 systemic therapy recommendations.

Immuno-oncology effectiveness in medicare population is the subject of a study of 20,000 Medicare patients published in JAMA.

Immunotherapy for early-stage lung cancer is the focus of a study presented at the American Society of Clinical Oncology (ASCO) annual meeting.

Amivantamab Approved for EGFR Exon 20–Positive NSCLC. FDA approval marks this as a first treatment for patients with EGFR exon 20 insertion.

Sotorasib Approved for KRAS G12C NSCLC. First FDA approved treatment for KRAS-positive non small cell lung cancer.

A new genomic study from the Ohio State University Cancer Center points to new treatment approaches for small-cell lung cancer.

A study shows promising results of a drug that helps the immune system fight cancer before surgery in patients with operable tumors.